Find care
Spravato vs TMS: Visits, Risks and Treatment Fit
Spravato vs TMS compares a depression medicine with a brain-stimulation treatment. Spravato is esketamine nasal spray given in a certified healthcare setting with monitoring. Repetitive transcranial magnetic stimulation, or rTMS, uses magnetic pulses; it does not administer ketamine or require anesthesia.
Both can enter a discussion when depression treatment has not helped enough. The choice depends on your history, the specific protocol offered, coverage and the visits you can sustain. This comparison cannot tell you which will work better for you.
The differences that matter before booking
| Question | Spravato | rTMS |
|---|---|---|
| What is delivered? | Esketamine medicine as a nasal spray | Magnetic stimulation through a device placed near the head |
| At home? | No; certified healthcare setting | Office or clinical treatment; confirm the actual device and protocol |
| What does the visit involve? | Administration plus required monitoring and discharge assessment | A stimulation session; protocol and session length vary |
| Does it require anesthesia? | Not general anesthesia; sedation is a possible effect | No anesthesia for rTMS |
| Main planning burden | Monitored visits and arranging a ride home | Repeated appointments; frequency depends on protocol |
| What needs screening? | Medical/psychiatric history, medicines and label contraindications | Medical history, seizure risk, implants/devices and protocol-specific suitability |
| Can a website choose for me? | No | No |
Sources: FDA Spravato Medication Guide and NIMH brain stimulation overview.
Spravato is a drug; TMS is a device-based procedure
That difference affects both the experience and the questions to ask. For Spravato, ask about the medicine, the monitoring team, recovery and how benefit and side effects are tracked. For TMS, ask about the device, the exact protocol, who prescribed it and who adjusts treatment.
“TMS” is an umbrella term in ordinary advertising. Standard rTMS, shorter-session protocols and accelerated courses can have different visit schedules and evidence. A provider should identify what it actually offers. Do not compare an accelerated program's schedule with another clinic's standard course without stating the difference.
Appointment burden can decide whether a plan is workable
Spravato requires at least two hours of monitoring after administration, and the healthcare provider decides when you can leave. The FDA guide requires a ride home and restricts driving until the next day after restful sleep. Account for the whole day, not just the medicine administration.
For standard rTMS, NIMH describes a typical course as frequent weekday sessions over several weeks; newer protocols can differ. Ask for the proposed calendar before you arrange transport, work or childcare. The clinic's offered protocol is the relevant schedule, not the shortest schedule seen in an advertisement. See NIMH.
Write down the number of visits, door-to-door time and likely time away from responsibilities for both options. A covered treatment can still be difficult to access if you cannot attend reliably.
Their risks are different
Spravato's label includes risks such as sedation, dissociation, respiratory depression, misuse and increased blood pressure. The FDA guide explains contraindications and conditions to discuss with the prescriber.
rTMS can cause scalp discomfort or headache; seizures are possible, although NIMH describes the risk as low. Device-specific screening matters, especially with implants or other relevant medical history. Use the NIMH overview and the device information supplied by your clinician.
No comparison of side-effect lists proves that one option is safer for a particular person. Ask which risks are relevant to your history and how the team reduces and responds to them.
Which has better results?
There is no honest universal winner from separate advertised success rates. A “response” rate and a “remission” rate measure different things. Trials also vary in patient selection, prior treatment, comparison group, follow-up and whether treatment continued.
Ask the clinician what evidence supports the specific treatment for a person with your diagnosis and treatment history. If a clinic quotes its own outcomes, ask how many patients were counted, how missing follow-up was handled, what measure defined improvement and when results were assessed. A percentage without those details is not enough to compare care.
This page does not turn separate studies into a head-to-head ranking or claim that either option guarantees durable improvement.
Compare the insured patient cost and the self-pay cost
For Spravato, request separate estimates for the medicine, evaluation, observation and ongoing visits. For TMS, request the total proposed course price, evaluation or mapping charges, and terms if treatment stops early. Ask both clinics about maintenance care and what it could add.
Have the insurer confirm the specific clinic, service, prior-authorization requirements and your responsibility. A clinic saying it “accepts insurance” does not establish that your course is approved.
The Spravato cost guide breaks down its bill. Our insurance guide explains why an approved medicine is not a promise of coverage.
Five questions for the consultation
- Why are you recommending this option for my history rather than another appropriate treatment?
- Which exact protocol or medicine plan would I receive, and how will you track benefit?
- What is the visit calendar, recovery requirement and transport plan?
- What will I owe if coverage is denied or I stop early?
- When do we reassess, and who coordinates with my existing mental-health clinician?
Do not stop current medicines based on this comparison. If your symptoms need urgent care, contact urgent or emergency services rather than waiting for a new clinic consultation.
Where to go next
Read the independent Spravato review for the clinic booking checklist. If you are also considering ketamine infusions or home programs, Spravato vs ketamine explains why these are separate options.
Checked November 17, 2026 against FDA and NIMH sources. We did not perform treatment testing or a clinical head-to-head comparison.